While intuitively in clinical practice we do recognize the lower overall effect of GDMT, higher number of intolerance and side-effects in women at high dosages, we have not found any clear signal on an existing heterogeneity in treatment efficacy of GDMT classes BB, RASi, MRA, and SGLT2 in contemporary HF trials. The gene discussed is SLC5A2; the disease is hydrops fetalis.